img

Global Transthyretin Amyloidosis (ATTR) Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Transthyretin Amyloidosis (ATTR) Market Research Report 2024

Transthyretin Amyloidosis (ATTR) is an autosomal dominant hereditary disease that occurs due to deposition of variant TTR (transthyretin) protein in humans. It is mainly characterized into two main types i.e. Hereditary ATTR (hATTR) and Wild-Type (wt) ATTR. While Hereditary ATTR is caused by point mutations within TTR allele, wild-type ATTR is caused by the misfolding of Wild-Type TTR. Major prevalence of Hereditary ATTR is observed in the 7MM, and this type has been further sub-classified into Familial Amyloidosis Polyneuropathy (FAP) and Familial Amyloidosis Cardiomyopathy (FAC).
According to MRAResearch’s new survey, global Transthyretin Amyloidosis (ATTR) market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Transthyretin Amyloidosis (ATTR) market research.
United States accounts for highest ATTR Amyloidosis Cases, followed by EU5 (Italy, France, Spain, Germany, UK) and Japan.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Transthyretin Amyloidosis (ATTR) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Pfizer
Alnylam Pharmaceuticals
Ionis Pharmaceuticals
Corino Therapeutics
Proclara Bioscience
Arcturus Therapeutics
Segment by Type
Hereditary ATTR (HATTR)
Wild-Type (WT) ATTR

Segment by Application


Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Transthyretin Amyloidosis (ATTR) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Transthyretin Amyloidosis (ATTR) Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Hereditary ATTR (HATTR)
1.2.3 Wild-Type (WT) ATTR
1.3 Market by Application
1.3.1 Global Transthyretin Amyloidosis (ATTR) Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Diagnostic Centers
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Transthyretin Amyloidosis (ATTR) Market Perspective (2018-2033)
2.2 Transthyretin Amyloidosis (ATTR) Growth Trends by Region
2.2.1 Global Transthyretin Amyloidosis (ATTR) Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Transthyretin Amyloidosis (ATTR) Historic Market Size by Region (2018-2023)
2.2.3 Transthyretin Amyloidosis (ATTR) Forecasted Market Size by Region (2024-2033)
2.3 Transthyretin Amyloidosis (ATTR) Market Dynamics
2.3.1 Transthyretin Amyloidosis (ATTR) Industry Trends
2.3.2 Transthyretin Amyloidosis (ATTR) Market Drivers
2.3.3 Transthyretin Amyloidosis (ATTR) Market Challenges
2.3.4 Transthyretin Amyloidosis (ATTR) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Transthyretin Amyloidosis (ATTR) Players by Revenue
3.1.1 Global Top Transthyretin Amyloidosis (ATTR) Players by Revenue (2018-2023)
3.1.2 Global Transthyretin Amyloidosis (ATTR) Revenue Market Share by Players (2018-2023)
3.2 Global Transthyretin Amyloidosis (ATTR) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Transthyretin Amyloidosis (ATTR) Revenue
3.4 Global Transthyretin Amyloidosis (ATTR) Market Concentration Ratio
3.4.1 Global Transthyretin Amyloidosis (ATTR) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Transthyretin Amyloidosis (ATTR) Revenue in 2022
3.5 Transthyretin Amyloidosis (ATTR) Key Players Head office and Area Served
3.6 Key Players Transthyretin Amyloidosis (ATTR) Product Solution and Service
3.7 Date of Enter into Transthyretin Amyloidosis (ATTR) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Transthyretin Amyloidosis (ATTR) Breakdown Data by Type
4.1 Global Transthyretin Amyloidosis (ATTR) Historic Market Size by Type (2018-2023)
4.2 Global Transthyretin Amyloidosis (ATTR) Forecasted Market Size by Type (2024-2033)
5 Transthyretin Amyloidosis (ATTR) Breakdown Data by Application
5.1 Global Transthyretin Amyloidosis (ATTR) Historic Market Size by Application (2018-2023)
5.2 Global Transthyretin Amyloidosis (ATTR) Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Transthyretin Amyloidosis (ATTR) Market Size (2018-2033)
6.2 North America Transthyretin Amyloidosis (ATTR) Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Transthyretin Amyloidosis (ATTR) Market Size by Country (2018-2023)
6.4 North America Transthyretin Amyloidosis (ATTR) Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Transthyretin Amyloidosis (ATTR) Market Size (2018-2033)
7.2 Europe Transthyretin Amyloidosis (ATTR) Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Transthyretin Amyloidosis (ATTR) Market Size by Country (2018-2023)
7.4 Europe Transthyretin Amyloidosis (ATTR) Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size (2018-2033)
8.2 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Region (2018-2023)
8.4 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Transthyretin Amyloidosis (ATTR) Market Size (2018-2033)
9.2 Latin America Transthyretin Amyloidosis (ATTR) Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Transthyretin Amyloidosis (ATTR) Market Size by Country (2018-2023)
9.4 Latin America Transthyretin Amyloidosis (ATTR) Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size (2018-2033)
10.2 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Country (2018-2023)
10.4 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Transthyretin Amyloidosis (ATTR) Introduction
11.1.4 Pfizer Revenue in Transthyretin Amyloidosis (ATTR) Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Alnylam Pharmaceuticals
11.2.1 Alnylam Pharmaceuticals Company Detail
11.2.2 Alnylam Pharmaceuticals Business Overview
11.2.3 Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Introduction
11.2.4 Alnylam Pharmaceuticals Revenue in Transthyretin Amyloidosis (ATTR) Business (2018-2023)
11.2.5 Alnylam Pharmaceuticals Recent Development
11.3 Ionis Pharmaceuticals
11.3.1 Ionis Pharmaceuticals Company Detail
11.3.2 Ionis Pharmaceuticals Business Overview
11.3.3 Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Introduction
11.3.4 Ionis Pharmaceuticals Revenue in Transthyretin Amyloidosis (ATTR) Business (2018-2023)
11.3.5 Ionis Pharmaceuticals Recent Development
11.4 Corino Therapeutics
11.4.1 Corino Therapeutics Company Detail
11.4.2 Corino Therapeutics Business Overview
11.4.3 Corino Therapeutics Transthyretin Amyloidosis (ATTR) Introduction
11.4.4 Corino Therapeutics Revenue in Transthyretin Amyloidosis (ATTR) Business (2018-2023)
11.4.5 Corino Therapeutics Recent Development
11.5 Proclara Bioscience
11.5.1 Proclara Bioscience Company Detail
11.5.2 Proclara Bioscience Business Overview
11.5.3 Proclara Bioscience Transthyretin Amyloidosis (ATTR) Introduction
11.5.4 Proclara Bioscience Revenue in Transthyretin Amyloidosis (ATTR) Business (2018-2023)
11.5.5 Proclara Bioscience Recent Development
11.6 Arcturus Therapeutics
11.6.1 Arcturus Therapeutics Company Detail
11.6.2 Arcturus Therapeutics Business Overview
11.6.3 Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Introduction
11.6.4 Arcturus Therapeutics Revenue in Transthyretin Amyloidosis (ATTR) Business (2018-2023)
11.6.5 Arcturus Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Transthyretin Amyloidosis (ATTR) Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Hereditary ATTR (HATTR)
Table 3. Key Players of Wild-Type (WT) ATTR
Table 4. Global Transthyretin Amyloidosis (ATTR) Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 5. Global Transthyretin Amyloidosis (ATTR) Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Transthyretin Amyloidosis (ATTR) Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Transthyretin Amyloidosis (ATTR) Market Share by Region (2018-2023)
Table 8. Global Transthyretin Amyloidosis (ATTR) Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 9. Global Transthyretin Amyloidosis (ATTR) Market Share by Region (2024-2033)
Table 10. Transthyretin Amyloidosis (ATTR) Market Trends
Table 11. Transthyretin Amyloidosis (ATTR) Market Drivers
Table 12. Transthyretin Amyloidosis (ATTR) Market Challenges
Table 13. Transthyretin Amyloidosis (ATTR) Market Restraints
Table 14. Global Transthyretin Amyloidosis (ATTR) Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Transthyretin Amyloidosis (ATTR) Market Share by Players (2018-2023)
Table 16. Global Top Transthyretin Amyloidosis (ATTR) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transthyretin Amyloidosis (ATTR) as of 2022)
Table 17. Ranking of Global Top Transthyretin Amyloidosis (ATTR) Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Transthyretin Amyloidosis (ATTR) Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Transthyretin Amyloidosis (ATTR) Product Solution and Service
Table 21. Date of Enter into Transthyretin Amyloidosis (ATTR) Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Transthyretin Amyloidosis (ATTR) Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Transthyretin Amyloidosis (ATTR) Revenue Market Share by Type (2018-2023)
Table 25. Global Transthyretin Amyloidosis (ATTR) Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 26. Global Transthyretin Amyloidosis (ATTR) Revenue Market Share by Type (2024-2033)
Table 27. Global Transthyretin Amyloidosis (ATTR) Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Transthyretin Amyloidosis (ATTR) Revenue Market Share by Application (2018-2023)
Table 29. Global Transthyretin Amyloidosis (ATTR) Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 30. Global Transthyretin Amyloidosis (ATTR) Revenue Market Share by Application (2024-2033)
Table 31. North America Transthyretin Amyloidosis (ATTR) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 32. North America Transthyretin Amyloidosis (ATTR) Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Transthyretin Amyloidosis (ATTR) Market Size by Country (2024-2033) & (US$ Million)
Table 34. Europe Transthyretin Amyloidosis (ATTR) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. Europe Transthyretin Amyloidosis (ATTR) Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Transthyretin Amyloidosis (ATTR) Market Size by Country (2024-2033) & (US$ Million)
Table 37. Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 38. Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Region (2024-2033) & (US$ Million)
Table 40. Latin America Transthyretin Amyloidosis (ATTR) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 41. Latin America Transthyretin Amyloidosis (ATTR) Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Transthyretin Amyloidosis (ATTR) Market Size by Country (2024-2033) & (US$ Million)
Table 43. Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Country (2024-2033) & (US$ Million)
Table 46. Pfizer Company Detail
Table 47. Pfizer Business Overview
Table 48. Pfizer Transthyretin Amyloidosis (ATTR) Product
Table 49. Pfizer Revenue in Transthyretin Amyloidosis (ATTR) Business (2018-2023) & (US$ Million)
Table 50. Pfizer Recent Development
Table 51. Alnylam Pharmaceuticals Company Detail
Table 52. Alnylam Pharmaceuticals Business Overview
Table 53. Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Product
Table 54. Alnylam Pharmaceuticals Revenue in Transthyretin Amyloidosis (ATTR) Business (2018-2023) & (US$ Million)
Table 55. Alnylam Pharmaceuticals Recent Development
Table 56. Ionis Pharmaceuticals Company Detail
Table 57. Ionis Pharmaceuticals Business Overview
Table 58. Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Product
Table 59. Ionis Pharmaceuticals Revenue in Transthyretin Amyloidosis (ATTR) Business (2018-2023) & (US$ Million)
Table 60. Ionis Pharmaceuticals Recent Development
Table 61. Corino Therapeutics Company Detail
Table 62. Corino Therapeutics Business Overview
Table 63. Corino Therapeutics Transthyretin Amyloidosis (ATTR) Product
Table 64. Corino Therapeutics Revenue in Transthyretin Amyloidosis (ATTR) Business (2018-2023) & (US$ Million)
Table 65. Corino Therapeutics Recent Development
Table 66. Proclara Bioscience Company Detail
Table 67. Proclara Bioscience Business Overview
Table 68. Proclara Bioscience Transthyretin Amyloidosis (ATTR) Product
Table 69. Proclara Bioscience Revenue in Transthyretin Amyloidosis (ATTR) Business (2018-2023) & (US$ Million)
Table 70. Proclara Bioscience Recent Development
Table 71. Arcturus Therapeutics Company Detail
Table 72. Arcturus Therapeutics Business Overview
Table 73. Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Product
Table 74. Arcturus Therapeutics Revenue in Transthyretin Amyloidosis (ATTR) Business (2018-2023) & (US$ Million)
Table 75. Arcturus Therapeutics Recent Development
Table 76. Research Programs/Design for This Report
Table 77. Key Data Information from Secondary Sources
Table 78. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Transthyretin Amyloidosis (ATTR) Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Transthyretin Amyloidosis (ATTR) Market Share by Type: 2022 VS 2033
Figure 3. Hereditary ATTR (HATTR) Features
Figure 4. Wild-Type (WT) ATTR Features
Figure 5. Global Transthyretin Amyloidosis (ATTR) Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 6. Global Transthyretin Amyloidosis (ATTR) Market Share by Application: 2022 VS 2033
Figure 7. Hospitals Case Studies
Figure 8. Ambulatory Surgical Centers Case Studies
Figure 9. Diagnostic Centers Case Studies
Figure 10. Transthyretin Amyloidosis (ATTR) Report Years Considered
Figure 11. Global Transthyretin Amyloidosis (ATTR) Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 12. Global Transthyretin Amyloidosis (ATTR) Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 13. Global Transthyretin Amyloidosis (ATTR) Market Share by Region: 2022 VS 2033
Figure 14. Global Transthyretin Amyloidosis (ATTR) Market Share by Players in 2022
Figure 15. Global Top Transthyretin Amyloidosis (ATTR) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transthyretin Amyloidosis (ATTR) as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Transthyretin Amyloidosis (ATTR) Revenue in 2022
Figure 17. North America Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 18. North America Transthyretin Amyloidosis (ATTR) Market Share by Country (2018-2033)
Figure 19. United States Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. Canada Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. Europe Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Europe Transthyretin Amyloidosis (ATTR) Market Share by Country (2018-2033)
Figure 23. Germany Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. France Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. U.K. Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Italy Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Russia Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Nordic Countries Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Share by Region (2018-2033)
Figure 31. China Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Japan Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. South Korea Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Southeast Asia Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. India Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Australia Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Latin America Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Latin America Transthyretin Amyloidosis (ATTR) Market Share by Country (2018-2033)
Figure 39. Mexico Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Brazil Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Share by Country (2018-2033)
Figure 43. Turkey Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Saudi Arabia Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Pfizer Revenue Growth Rate in Transthyretin Amyloidosis (ATTR) Business (2018-2023)
Figure 46. Alnylam Pharmaceuticals Revenue Growth Rate in Transthyretin Amyloidosis (ATTR) Business (2018-2023)
Figure 47. Ionis Pharmaceuticals Revenue Growth Rate in Transthyretin Amyloidosis (ATTR) Business (2018-2023)
Figure 48. Corino Therapeutics Revenue Growth Rate in Transthyretin Amyloidosis (ATTR) Business (2018-2023)
Figure 49. Proclara Bioscience Revenue Growth Rate in Transthyretin Amyloidosis (ATTR) Business (2018-2023)
Figure 50. Arcturus Therapeutics Revenue Growth Rate in Transthyretin Amyloidosis (ATTR) Business (2018-2023)
Figure 51. Bottom-up and Top-down Approaches for This Report
Figure 52. Data Triangulation
Figure 53. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries